To our current knowledge, this is the first investigation on the protective effect of an ongoing SGLT2-i therapy in diabetic patients with MI, regardless of the concomitant glucose-lowering therapy or previous CABG (coronary artery bypass graft) focusing on the anticipated and actual myocardial damage based on the coronary angiogram. Here, SLC5A2 is linked to myocardial infarction.